Residual disease subtyping predicts survival and guides adjuvant immunotherapy in esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy.

Front Immunol · 2026 · PMC13038938 · PMID 41929523

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Concurrently, OS analysis yielded an HR of 0.47 (95% CI: 0.19-1.16, P = 0.104), while numerically favoring the treatment group, did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.